Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Homosexuality, Male | 1 | 2024 | 62 | 0.920 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 32 | 0.900 |
Why?
|
| Hepatitis C | 1 | 2024 | 364 | 0.710 |
Why?
|
| Veterans | 1 | 2024 | 1733 | 0.400 |
Why?
|
| HIV Infections | 1 | 2024 | 1855 | 0.400 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 359 | 0.210 |
Why?
|
| Prevalence | 2 | 2025 | 2404 | 0.190 |
Why?
|
| Neoplasm Staging | 1 | 2025 | 1213 | 0.180 |
Why?
|
| Risk Factors | 2 | 2024 | 10016 | 0.170 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 455 | 0.170 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 36 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 32 | 0.160 |
Why?
|
| Middle Aged | 4 | 2024 | 25993 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 2480 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 993 | 0.140 |
Why?
|
| Incidence | 1 | 2024 | 3044 | 0.130 |
Why?
|
| Texas | 1 | 2024 | 3563 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3371 | 0.130 |
Why?
|
| Ethoxzolamide | 1 | 2015 | 2 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2024 | 3317 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 338 | 0.110 |
Why?
|
| Mutation | 2 | 2024 | 5765 | 0.110 |
Why?
|
| Adult | 2 | 2024 | 29011 | 0.110 |
Why?
|
| Male | 6 | 2024 | 60080 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 227 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 1862 | 0.100 |
Why?
|
| Aged | 3 | 2025 | 19095 | 0.100 |
Why?
|
| United States | 2 | 2025 | 10651 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1439 | 0.100 |
Why?
|
| Young Adult | 1 | 2024 | 8837 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1591 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 332 | 0.080 |
Why?
|
| Humans | 8 | 2025 | 123070 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 467 | 0.070 |
Why?
|
| DNA Damage | 1 | 2010 | 512 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 617 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 502 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2006 | 313 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2024 | 16039 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 643 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3239 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2758 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 1236 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2006 | 1100 | 0.060 |
Why?
|
| SEER Program | 1 | 2025 | 194 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 2055 | 0.050 |
Why?
|
| Genotype | 2 | 2019 | 2533 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 1112 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4513 | 0.040 |
Why?
|
| Female | 5 | 2025 | 65529 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2015 | 96 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 2015 | 122 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 143 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 861 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6027 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6372 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 669 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1214 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 269 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 340 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 745 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 426 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 488 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5048 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2014 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2010 | 93 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 12123 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 162 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3654 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2826 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 1475 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2006 | 51 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2006 | 48 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2006 | 391 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 371 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2581 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2395 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1782 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2307 | 0.010 |
Why?
|
| Animals | 2 | 2015 | 33791 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4286 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 17538 | 0.010 |
Why?
|